Regenesome Co., Ltd. (Headquarters: Minato-ku, Tokyo; Representative Director: Zentaro Sakuma), a subsidiary of Space Seed Holdings Inc. (Headquarters: Minato-ku, Tokyo; Representative Director: Kengo Suzuki), announced its participation in the "IVS Startup Market," an exhibition and networking space at "IVS2026" (July 1-3, 2026, at Kyoto Miyako Messe and other venues), Japan's largest startup conference hosted by Headline Japan Inc. Regenesome will exhibit on the second day, DAY2 (July 2, 2026), at booth number SA-33. This exhibition is considered one of the initiatives to promote the societal implementation of aging control and regenerative medicine using nanoparticles. Exhibition Details Item Details Event Name IVS2026 / IVS Startup Market Dates July 1 (Wed) - July 3 (Fri), 2026 Exhibiting Company Regenesome Co., Ltd. Exhibition Date July 2, 2026 (DAY2) Booth Number SA-33 Venue Kyoto Miyako Messe and other venues (Sakyo-ku, Kyoto City) Organizer Headline Japan Inc. "IVS Startup Market" is an exhibition and networking space where leading domestic startups gather. Regenesome views this market, which brings together investors, corporations, research institutions, and potential partners, as a platform for dialogue to deliver nanoparticle technology and aging control research to society, and will introduce its business at booth SA-33 on DAY2. Click here for IVS event information What Regenesome Aims to Convey Regenesome is a bio-venture company aiming to "solve challenges of aging with biotechnology" and strives to establish aging control and regenerative medicine using nanoparticles such as liposomes. The company's mission is to "provide anti-aging technology applicable to Earth, necessary for humanity to expand its living sphere to the moon in 2040," and its vision is to "demonstrate anti-aging technology that extends healthy life expectancy by 2030." At this market, Regenesome plans to introduce its research and development directions and their application to longe